Compare Heron Therapeutics Inc (HRTX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Verizon Communications Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Verizon Communications Inc trades at $41.65 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 2831.5× Heron Therapeutics Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Verizon Communications Inc for 109 Days on average.
| HRTX | VZ | |
|---|---|---|
Market Cap | $68.01M | $192.57B |
Volume | 1,891,941 | 20,940,094 |
Sector | Health | Media |
52-Week High | $1.49 | $51.45 |
52-Week Low | $0.27 | $38.40 |
Typical Hold Time | 35 Days | 109 Days |
Enterprise Value | $174.75M | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Verizon (VZ) trades at $46.35, up 1.27% today, with a bearish technical signal but strong fundamentals including a P/E of 12.07 and net income margin of 11.64%. Recent earnings beats and a $0.71 dividend highlight stability, while cash flow improved to $14.86B in 2025. The stock is near its consensus price target of $48.17, with analyst sentiment mixed but leaning hold.
Outlook: Verizon offers value with steady dividends and cash flow, but faces competition and debt risks. Upside depends on execution in wireless markets; cautious optimism is warranted given technical weakness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
